Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683252 | 0.91 | TSHR (0.32) | TSHRPPARDTP53TDP1SMN1; SMN2 | |
| SCHEMBL4637563 | 0.82 | PPARD (0.35) | TSHRPPARDTP53TDP1SMN1; SMN2 | |
| SCHEMBL18048500 | 0.80 | PPARD (0.32) | TSHRPPARD | |
| SCHEMBL10590583 | 0.79 | TSHR (0.41) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL1683251 | 0.78 | TSHR (0.37) | TSHRPPARDTP53TDP1SMN1; SMN2 | |
| SCHEMBL8820544 | 0.75 | TSHR (0.39) | TSHRPPARDTP53TDP1SMN1; SMN2 | |
| SCHEMBL2079486 | 0.75 | TSHR (0.39) | TSHRPPARDTP53TDP1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3432138 | 0.75 | S1PR1 (0.46) | TSHRPPARDS1PR1S1PR3S1PR2 | |
| SCHEMBL2987745 | 0.74 | MEN1 (0.30) | — | |
| SCHEMBL7490235 | 0.73 | TSHR (0.37) | TSHRPPARDTP53TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8795884-B2 | Nonaqueous secondary battery and electronic device | HITACHI MAXELL, LTD. (JP) | 2014-08-05 | — | — | US | claimed |
| US-20110052980-A1 | NONAQUEOUS SECONDARY BATTERY AND ELECTRONIC DEVICE | MAXELL, LTD. (JP) | 2011-03-03 | — | — | US | claimed |
| EP-0396841-B1 | Fluorinated arachidonic acid derivatives | MERRELL DOW PHARMA (US) | 1994-02-02 | — | — | EP | claimed |
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2023-05-25 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2698859-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND ELECTRICITY-STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2016-07-27 | — | — | EP | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2121555-B1 | NEW METHOD FOR PREPARING UNSATURATED FATTY HYDROXY-ACIDS | FABRE PIERRE DERMO COSMETIQUE (FR) | 2014-03-12 | — | — | EP | disclosed |
| US-4335248-A | ANTITUMOR AGENTS AND IN THE TREATMENT OF ACNE | HOFFMANN-LA ROCHE INC. (US) | 1982-06-15 | — | — | US | disclosed |
| US-4321209-A | Fluorinated aromatic polyenes | HOFFMANN-LA ROCHE INC. (US) | 1982-03-23 | — | — | US | disclosed |
| US-4299995-A | ANTITUMOR AGENTS AND TREATMENT OF SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1981-11-10 | — | — | US | disclosed |
| US-4266073-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4231944-A | 9-FURYL SUBSTITUTED, 4- OR 6-FLUORO DERIVATIVES OF RETINOIC ACID, ANTITUMOR AGENTS, TREATMENT OF ACNE | HOFFMANN-LA ROCHE INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-4201727-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4171318-A | 9-(SUBSTITUTED PHENYL), 4 OR 6-FLUORO-RETINOIC ACID DERIVATIVES, ANTITUMOR AND ANTIACNE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4169100-A | FLUORO AND TRIFLUOROMETHYL SUBSTITUTED 9-(4-ALKOXY-2,3,6-TRIALKYLPHENYL)-2,4,6,8-NONATETRAENOIC ACIDS, ESTERS AND AMIDES, ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4137246-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159961-A1 | BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS | GGPS1, DHPS, FDPS | TSHR 3943/4885PPARD 1180/4885TP53 2052/4885 |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | TSHR 2638/4885PPARD 4383/4885TP53 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.